Brainify.AI

Brainify.AI operates at the intersection of neurotechnology, clinical research software, digital health and AI-enabled diagnostics. Its positioning differs from consumer neurotechnology companies such as Muse and Emotiv, which primarily emphasize hardware, personal monitoring or developer access, because Brainify.AI combines EEG capture, multimodal clinical data structuring and biomarker development for biopharma and healthcare workflows. It also occupies a different niche from clinical neurodiagnostic businesses such as Neuroelectrics and Kernel, whose offerings are more closely associated with specialized measurement hardware or imaging modalities. Brainify.AI’s stated focus is the conversion of brain signals into deployable biomarkers for patient stratification, trial design, treatment-response prediction and real-world evidence. The company’s Datahub and Foundational Brain Model are intended to support both research programs and standardized provider assessments, while BREEG provides a portable EEG pathway. Its 2025 seed financing of $2.3 million and total funding of $4.05 million indicate an early-stage scale relative to larger neurotechnology competitors. The main differentiator is breadth across drug development, clinical care and longevity, although public information does not establish comparative regulatory approvals, commercial revenue or market share.

Brainify.AI’s trajectory shows a progression from early research infrastructure to broader commercial deployment. Founded on Feb 27, 2021, the company raised six rounds totaling $4.05 million between 2021 and 2025. Initial pre-seed financing included $200,000 in April 2021, followed by $300,000 in February 2022, $100,000 in November 2022, $1 million in January 2023 and $150,000 from a round involving Merck Digital Sciences Studio in October 2023. The inflection point was the $2.3 million seed round announced on Aug 31, 2025, which provided the largest recorded financing for expansion. Product development has moved beyond a research platform: the company reports infrastructure supporting more than 150,000 subjects in its Foundational Brain Model, 500,000 brain scans and 2.7 million patients. Partnerships with HB Bio, Negev Labs, Newleos Therapeutics and Clerkenwell Health indicate application in drug development and precision psychiatry. The 2026 launch of Brainify.AI Longevity at a Riyadh clinic adds a wellness and hospitality distribution channel.